New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

UCMA Polyclonal Antibody, Cy3 Conjugated

Applications

  • WB

Predicted Reactivity

  • Human
  • Mouse
  • Rat
Overview
Catalog # bs-12378R-Cy3
Product Name UCMA Polyclonal Antibody, Cy3 Conjugated
Applications WB
Predicted Reactivity Human, Mouse, Rat
Specifications
Conjugation Cy3
Host Rabbit
Source KLH conjugated synthetic peptide derived from human UCMA
Immunogen Range 21-120/138
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 221044
Subcellular location Secreted, Extracellular matrix
Synonyms C10orf49; Gla rich protein; Gla-rich protein; Grp; GRP; OTTMUSP00000011599; RP23-272I15.1; UCMA; Ucma-C; UCMA_HUMAN; Unique cartilage matrix associated protein; Unique cartilage matrix-associated protein C-terminal fragment; Upper zone of growth plate and cartilage matrix associated.
Background UCMA is a 138 amino acid secreted protein that is highly expressed in resting chrondrocytes in developing long bones and is thought to function in the early phase of chrondrocyte differentiation. A furin-like protease processes UCMA into an N-terminal 37 amino acid peptide and a C-terminal 74 amino acid peptide, which is referred to as Unique cartilage matrix-associated protein C-terminal fragment (Ucma-C). Introduction of recombinant Ucma-C interferes with osteogenic differentiation of mesenchymal stem cells, MC3T3-E1 preosteoblasts and primary osteoblasts. This suggests that Ucma may be involved in the negative regulation of osteogenic differentiation of osteochondrogenic precursor cells at the cartilage-bone interface and in peripheral zones of fetal cartilage.
Application Dilution
WB 1:300-5000